Friday, August 15, 2025
11:00 AM - 12:00 PM Central Time (CT)
Virtual
CCO Simulcast | Host Group AR
Little Rock, Arkansas
Gastroenterologists and gastroenterology nurse practitioners and physician associates who manage patients with Crohn’s disease (CD) will learn about treat-to-target strategies, noninvasive imaging, and the newest treatment targets to improve patient care.
Agenda:
Welcome & Introduction
Treat to Target in CD: Where Are We Now?
Noninvasive Imaging Tools to Assess Mucosal and Transmural Inflammation
Evolving Role of Histology in CD Management
Summary of Clinical Takeaways
Final Q&A
Goal statement:
The goal of this activity is to improve knowledge, competence, and performance among GI HCP learners on treat-to-target strategies in CD, noninvasive imaging, and the newest treatment targets, including histological endpoints, to optimize and individualize patient care.
Target audience:
The target audience for this education is gastroenterologists, gastroenterology nurse practitioners and physician associates who manage patients with CD.
Learning objectives:
Upon completion of this activity, participants should be able to:
- Evaluate treatment response and treatment advancement needs within a treat-to-target framework for patients with moderate to severe CD
- Integrate noninvasive imaging-based assessments of mucosal and transmural inflammation into treatment response monitoring for patients with CD
- Utilize histological analysis in management decisions for patients with CD
Faculty:
Jordan E. Axelrad, MD, MPH, FACG
Assistant Professor
Gastroenterology
NYU Grossman School of Medicine
New York, New York
Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health
Associate Professor of Medicine
NYU Grossman School of Medicine
New York, New York
CME and MOC information:
Nurse Practitioners/Nurses: 1.00 Nursing contact hour Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit Physicians: maximum of 1.00 AMA PRA Category 1 Credit™
Physicians ABIM MOC: maximum of 1.00 Medical Knowledge MOC point
Supporters:
This activity is supported by an educational grant from Lilly.
Sponsor:
Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC and the American Gastroenterological Association (AGA).
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Jordan E. Axelrad, MD, MPH, FACG: consultant/advisor/speaker: AbbVie, Abviax, Adiso, bioMérieux, Bristol Myers Squibb, Celltrion, Ferring, Fresenius, Janssen, Merck, Pfizer, Vedanta; researcher: BioFire Diagnostics, Genentech, Janssen.
The planners and content peer reviewers from Clinical Care Options, LLC and the American Gastroenterological Association (AGA) do not have any relevant financial relationships to disclose.